Who Goes to Jail When AI Fails? Compliance in the Gen AI Era

Generative AI could unlock massive economic value for life sciences, but only 5% of companies are seeing the benefits. Maya and Sam break down a new IQVIA white paper on how pharma and medtech Quality Assurance and Regulatory Affairs (QA/RA) teams can safely deploy AI without triggering compliance disasters.

Key points

• Generative AI has the potential to unlock massive economic value for the life sciences industry, yet only 5% of organizations have realized these benefits.
• In a poll of healthcare companies, 44% cited regulation as their top concern for AI implementation, while cost was the lowest at just 4%.
• Legal experts note that regulation is the top concern because non-compliance is a potential 'go-to-jail' moment for risk-averse organizations.
• AI is highly effective at monitoring other AI systems, with large companies using multiple tools simultaneously to cross-interrogate and triangulate outputs.
• Companies must navigate both 'vertical' regulations for specific medical products and 'horizontal' regulations that span industries, such as the EU AI Act.

Source: AI in Life Science Quality Management and Regulatory Affairs: Global Compliance and Strategic Readiness - IQVIA, 2025

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/who-goes-to-jail-when-ai-fails-compliance-in-the-gen-ai-era-d72386